-
1
-
-
11144358403
-
Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
-
Afdhal, N. H., Dieterich, D. T., Pockros, P. J., Schiff, E. R., Shiffman, M. L., Sulkowski, M. S., Bowers, P. (2004). Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology, 126, 1302-1311.
-
(2004)
Gastroenterology
, vol.126
, pp. 1302-1311
-
-
Afdhal, N.H.1
Dieterich, D.T.2
Pockros, P.J.3
Schiff, E.R.4
Shiffman, M.L.5
Sulkowski, M.S.6
Bowers, P.7
-
2
-
-
84857109493
-
-
® (darbepoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
-
® (darbepoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
-
(2008)
-
-
-
3
-
-
84857109995
-
-
® (epoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
-
® (epoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
-
(2008)
-
-
-
4
-
-
33748168698
-
Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches
-
Asnis, G. M., & De La Garza R II (2006). Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches. Journal of Clinical Gastroenterology, 40, 322-335.
-
(2006)
Journal of Clinical Gastroenterology
, vol.40
, pp. 322-335
-
-
Asnis, G.M.1
De La Garza II, R.2
-
5
-
-
66949176133
-
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results
-
Bacon, B. R., Shiffman, M. L., Mendes, F., Ghalib, R., Hassanein, T., Morelli, G., Gitlin, N. (2009). Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology, 49, 1838-1846.
-
(2009)
Hepatology
, vol.49
-
-
Bacon, B.R.1
Shiffman, M.L.2
Mendes, F.3
Ghalib, R.4
Hassanein, T.5
Morelli, G.6
Gitlin, N.7
-
6
-
-
33645992473
-
Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
-
Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T., Zeuzem, S. (2006). Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology, 130, 1086-1097.
-
(2006)
Gastroenterology
, vol.130
, pp. 1086-1097
-
-
Berg, T.1
von Wagner, M.2
Nasser, S.3
Sarrazin, C.4
Heintges, T.5
Gerlach, T.6
Zeuzem, S.7
-
7
-
-
79960719261
-
-
Site and size of interferon pegylation alters affinity to the IFNAR2-extracellular domain. Presented at the 6th International Cytokine Conference, Vienna, Austria.
-
Bordens, R., Xie, L., Wylie, D., Grace, M., & Schreiber, G. (2006). Site and size of interferon pegylation alters affinity to the IFNAR2-extracellular domain. Presented at the 6th International Cytokine Conference, Vienna, Austria.
-
(2006)
-
-
Bordens, R.1
Xie, L.2
Wylie, D.3
Grace, M.4
Schreiber, G.5
-
8
-
-
10344230440
-
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial
-
Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Perronne, C. (2004). Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. Journal of the American Medical Association, 292, 2839-2848.
-
(2004)
Journal of the American Medical Association
, vol.292
, pp. 2839-2848
-
-
Carrat, F.1
Bani-Sadr, F.2
Pol, S.3
Rosenthal, E.4
Lunel-Fabiani, F.5
Benzekri, A.6
Perronne, C.7
-
9
-
-
0013690671
-
-
Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Retrieved March 28, 2008, from
-
Centers for Disease Control and Prevention. (2008). Hepatitis C fact sheet. Centers for Disease Control and Prevention. Retrieved March 28, 2008, from
-
(2008)
Hepatitis C fact sheet
-
-
-
10
-
-
33646270395
-
Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease
-
Chevaliez, S., & Pawlotsky, J.-M. (2006). Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. International Journal of Medical Sciences, 3, 35-40.
-
(2006)
International Journal of Medical Sciences
, vol.3
, pp. 35-40
-
-
Chevaliez, S.1
Pawlotsky, J.-M.2
-
11
-
-
3342892905
-
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
-
Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., van der Horst, C. (2004). Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351, 451-459.
-
(2004)
New England Journal of Medicine
, vol.351
, pp. 451-459
-
-
Chung, R.T.1
Andersen, J.2
Volberding, P.3
Robbins, G.K.4
Liu, T.5
Sherman, K.E.6
van der Horst, C.7
-
12
-
-
11144252779
-
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin
-
Collantes, R. S., & Younossi, Z. M. (2005). The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. Journal of Clinical Gastroenterology, 39, S9-S13.
-
(2005)
Journal of Clinical Gastroenterology
, vol.39
-
-
Collantes, R.S.1
Younossi, Z.M.2
-
13
-
-
33845641280
-
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy
-
Del Rio, R. A., Post, A. B., & Singer, M. E. (2006). Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology, 44, 1598-1606.
-
(2006)
Hepatology
, vol.44
, pp. 1598-1606
-
-
Del Rio, R.A.1
Post, A.B.2
Singer, M.E.3
-
14
-
-
30044432484
-
American gastroenterological association technical review on the management of hepatitis C
-
Dienstag, J. L., & McHutchison, J. G. (2006). American gastroenterological association technical review on the management of hepatitis C. Gastroenterology, 130, 231-264.
-
(2006)
Gastroenterology
, vol.130
, pp. 231-264
-
-
Dienstag, J.L.1
McHutchison, J.G.2
-
15
-
-
0242437747
-
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa
-
Dieterich, D. T., Wasserman, R., Brau, N., Hassanein, T. I., Bini, E. J., Bowers, P. J., and Sulkowski, M.S. (2003). Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology, 98, 2491-2499.
-
(2003)
American Journal of Gastroenterology
, vol.98
, pp. 2491-2499
-
-
Dieterich, D.T.1
Wasserman, R.2
Brau, N.3
Hassanein, T.I.4
Bini, E.J.5
Bowers, P.J.6
Sulkowski, M.S.7
-
16
-
-
33845645008
-
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
-
Everson, G. T., Hoefs, J. C., Seeff, L. B., Bonkovsky, H. L., Naishadham, D., Shiffman, M. L., Morishima, C. (2006). Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology, 44, 1675-1684.
-
(2006)
Hepatology
, vol.44
, pp. 1675-1684
-
-
Everson, G.T.1
Hoefs, J.C.2
Seeff, L.B.3
Bonkovsky, H.L.4
Naishadham, D.5
Shiffman, M.L.6
Morishima, C.7
-
17
-
-
48749099989
-
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
-
Ferenci, P., Laferl, H., Scherzer, T. M., Gschwantler, M., Maieron, A., Brunner, H., Steindl-Munda, P. (2008). Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology, 135, 451-458.
-
(2008)
Gastroenterology
, vol.135
, pp. 451-458
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
Gschwantler, M.4
Maieron, A.5
Brunner, H.6
Steindl-Munda, P.7
-
18
-
-
79960731253
-
Prospective study of mother-to-infant transmission of hepatitis C virus: A 10-year survey (1990-2000)
-
Ferrero, S., Lungaro, P., Bruzzone, B. M., Gotta, C., Bentivoglio, G., & Ragni, N. (2003). Prospective study of mother-to-infant transmission of hepatitis C virus: A 10-year survey (1990-2000). Obstetrical and Gynecological Survey, 58, 636-637.
-
(2003)
Obstetrical and Gynecological Survey
, vol.58
, pp. 636-637
-
-
Ferrero, S.1
Lungaro, P.2
Bruzzone, B.M.3
Gotta, C.4
Bentivoglio, G.5
Ragni, N.6
-
19
-
-
0036830454
-
Side effects of therapy of hepatitis C and their management
-
Fried, M. W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36, S237-S244.
-
(2002)
Hepatology
, vol.36
-
-
Fried, M.W.1
-
20
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales F. L. Jr., ... Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347, 975-982.
-
(2002)
New England Journal of Medicine
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales Jr, F.L.6
Yu, J.7
-
21
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: An update
-
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49, 1335-1374.
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
22
-
-
20044385757
-
Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway
-
Grace, M. J., Lee, S., Bradshaw, S., Chapman, J., Spond, J., Cox, S., Bordens, R. (2005). Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. Journal of Biological Chemistry, 280, 6327-6336.
-
(2005)
Journal of Biological Chemistry
, vol.280
, pp. 6327-6336
-
-
Grace, M.J.1
Lee, S.2
Bradshaw, S.3
Chapman, J.4
Spond, J.5
Cox, S.6
Bordens, R.7
-
23
-
-
1542378867
-
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis, S. J., Sette, H. Jr., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ackrill, A.M. (2004). Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140, 346-355.
-
(2004)
Annals of Internal Medicine
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr, H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
Ackrill, A.M.7
-
24
-
-
0036430340
-
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C
-
Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Howell, C.D. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry, 7, 942-947.
-
(2002)
Molecular Psychiatry
, vol.7
, pp. 942-947
-
-
Hauser, P.1
Khosla, J.2
Aurora, H.3
Laurin, J.4
Kling, M.A.5
Hill, J.6
Howell, C.D.7
-
25
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Zeuzem, S. (2009). Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine, 360, 1839-1850.
-
(2009)
New England Journal of Medicine
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
Zeuzem, S.7
-
26
-
-
79959749091
-
-
Hoffman La Roche, Nutley, NJ: Hoffman-La Roche, Inc.
-
Hoffman La Roche, Inc. (2008). Pegasys (peginterferon alfa-2a). Nutley, NJ: Hoffman-La Roche, Inc.
-
(2008)
Pegasys (peginterferon alfa-2a)
-
-
-
27
-
-
0036828784
-
The burden of hepatitis C in the United States
-
Kim, W. R. (2002). The burden of hepatitis C in the United States. Hepatology, 36, S30-S34.
-
(2002)
Hepatology
, vol.36
-
-
Kim, W.R.1
-
28
-
-
13244249842
-
Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression
-
Kraus, M. R., Schafer, A., Al-Taie, O., & Scheurlen, M. (2005). Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. Journal of Viral Hepatitis, 12, 96-100.
-
(2005)
Journal of Viral Hepatitis
, vol.12
, pp. 96-100
-
-
Kraus, M.R.1
Schafer, A.2
Al-Taie, O.3
Scheurlen, M.4
-
29
-
-
0035999141
-
Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C
-
Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2002). Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 16, 1091-1099.
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, pp. 1091-1099
-
-
Kraus, M.R.1
Schafer, A.2
Faller, H.3
Csef, H.4
Scheurlen, M.5
-
30
-
-
84857109999
-
-
Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron™ (peginterferon alfa-2b)/Ribavirin in treatment-naïve subject with genotype-1 CHC [abstract]. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
-
Kwo, P., Lawitz, E., McCone, J., Schiff, E., Vierling, J., Pound, D., Albrecht, J.K. (2008). Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron™ (peginterferon alfa-2b)/Ribavirin in treatment-naïve subject with genotype-1 CHC [abstract]. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
-
(2008)
-
-
Kwo, P.1
Lawitz, E.2
McCone, J.3
Schiff, E.4
Vierling, J.5
Pound, D.6
Albrecht, J.K.7
-
31
-
-
59149085501
-
The global burden of hepatitis C
-
Lavanchy, D. (2009). The global burden of hepatitis C. Liver International, 29, 74-81.
-
(2009)
Liver International
, vol.29
, pp. 74-81
-
-
Lavanchy, D.1
-
32
-
-
67650558336
-
Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-RIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin
-
Lawitz, E. J., Zaman, A., Muir, A. J., Shiffman, M. L., Yoffe, B., Zhang, T., Hausman, D.F. (2008). Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-RIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin. Hepatology 48, 385A.
-
(2008)
Hepatology
, vol.48
-
-
Lawitz, E.J.1
Zaman, A.2
Muir, A.J.3
Shiffman, M.L.4
Yoffe, B.5
Zhang, T.6
Hausman, D.F.7
-
33
-
-
44449146437
-
Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin
-
Leevy, C. B. (2008). Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Digestive Diseases and Sciences, 53, 1961-1966.
-
(2008)
Digestive Diseases and Sciences
, vol.53
, pp. 1961-1966
-
-
Leevy, C.B.1
-
34
-
-
2442425456
-
Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-α: A prospective case series and a discussion of biological mechanisms
-
Maddock, C., Baita, A., Orru, M. G., Sitzia, R., Costa, A., Muntoni, E., ... Pariante, C.M. (2004). Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-α: A prospective case series and a discussion of biological mechanisms. Journal of Psychopharmacology, 18, 41-46.
-
(2004)
Journal of Psychopharmacology
, vol.18
, pp. 41-46
-
-
Maddock, C.1
Baita, A.2
Orru, M.G.3
Sitzia, R.4
Costa, A.5
Muntoni, E.6
Pariante, C.M.7
-
35
-
-
16844368692
-
Psychopathological symptoms during interferon-α and ribavirin treatment: Effects on virologic response
-
Maddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., ... Pariante, C.M. (2005). Psychopathological symptoms during interferon-α and ribavirin treatment: Effects on virologic response. Molecular Psychiatry, 10, 332-333.
-
(2005)
Molecular Psychiatry
, vol.10
, pp. 332-333
-
-
Maddock, C.1
Landau, S.2
Barry, K.3
Maulayah, P.4
Hotopf, M.5
Cleare, A.J.6
Pariante, C.M.7
-
36
-
-
38649090347
-
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
-
Mangia, A., Minerva, N., Bacca, D., Cozzolongo, R., Ricci, G. L., Carretta, V., ... Andriulli, A. (2008). Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology, 47, 43-50.
-
(2008)
Hepatology
, vol.47
, pp. 43-50
-
-
Mangia, A.1
Minerva, N.2
Bacca, D.3
Cozzolongo, R.4
Ricci, G.L.5
Carretta, V.6
Andriulli, A.7
-
37
-
-
20544443172
-
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
-
Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., ... Andriulli, A. (2005). Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 352, 2609-2617.
-
(2005)
New England Journal of Medicine
, vol.352
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
Ricci, G.L.4
Carretta, V.5
Persico, M.6
Andriulli, A.7
-
38
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., ... Albrecht, J.K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Albrecht, J.K.7
-
39
-
-
51249090533
-
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
-
Maylin, S., Martinot-Peignoux, M., Moucari, R., Boyer, N., Ripault, M. P., Cazals-Hatem, D., ... Marcellin, P. (2008). Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology, 135, 821-829.
-
(2008)
Gastroenterology
, vol.135
, pp. 821-829
-
-
Maylin, S.1
Martinot-Peignoux, M.2
Moucari, R.3
Boyer, N.4
Ripault, M.P.5
Cazals-Hatem, D.6
Marcellin, P.7
-
40
-
-
30344436353
-
The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice
-
McHutchison, J. G., Bartenschlager, R., Patel, K., & Pawlotsky, J.-M. (2006). The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice. Journal of Hepatology, 44, 411-421.
-
(2006)
Journal of Hepatology
, vol.44
, pp. 411-421
-
-
McHutchison, J.G.1
Bartenschlager, R.2
Patel, K.3
Pawlotsky, J.-M.4
-
41
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., ... Muir, A.J. (2009a). Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine, 360, 1827-1838.
-
(2009)
New England Journal of Medicine
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
Muir, A.J.7
-
42
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavarin for treatment of hepatitis C infection
-
McHutchison, J. G., Lawitz, E. J., Shiffman, M. L., Muir, A. J., Galler, G. W., McCone, J., ... Sulkowski, M.S. (2009b). Peginterferon alfa-2b or alfa-2a with ribavarin for treatment of hepatitis C infection. New England Journal of Medicine, 361, 580-593.
-
(2009)
New England Journal of Medicine
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
Muir, A.J.4
Galler, G.W.5
McCone, J.6
Sulkowski, M.S.7
-
43
-
-
0036788338
-
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
-
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., ... Albrecht, J.K. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123, 1061-1069.
-
(2002)
Gastroenterology
, vol.123
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
Poynard, T.4
Lindsay, K.L.5
Trepo, C.6
Albrecht, J.K.7
-
44
-
-
2442665224
-
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
-
amp; the Atlantic Coast Hepatitis Treatment Group.
-
Muir, A. J., Bornstein, J. D., Killenberg, P. G., & the Atlantic Coast Hepatitis Treatment Group. (2004). Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine, 350, 2265-2271.
-
(2004)
New England Journal of Medicine
, vol.350
, pp. 2265-2271
-
-
Muir, A.J.1
Bornstein, J.D.2
Killenberg, P.G.3
-
45
-
-
33845616297
-
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
-
Muir, A. J., & McHutchison, J. G. (2006). Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology, 44, 1400-1403.
-
(2006)
Hepatology
, vol.44
, pp. 1400-1403
-
-
Muir, A.J.1
McHutchison, J.G.2
-
46
-
-
79960738740
-
-
The use of growth factors (GF) in the re-treatment of patients with chronic hepatitis C (CHC) who are previous non responders (NR) to combination therapy. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain.
-
Nader, F., Bai, C., Terra, K., Gurung, C., Srishord, M., Fang, Y., ... Younossi, Z. M. (2007). The use of growth factors (GF) in the re-treatment of patients with chronic hepatitis C (CHC) who are previous non responders (NR) to combination therapy. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain.
-
(2007)
-
-
Nader, F.1
Bai, C.2
Terra, K.3
Gurung, C.4
Srishord, M.5
Fang, Y.6
Younossi, Z.M.7
-
47
-
-
66849088067
-
-
National Institute of Diabetes and Digestive and Kidney Diseases. (). National Digestive Diseases Information Clearinghouse. Retrieved March 16, 2009, from
-
National Institute of Diabetes and Digestive and Kidney Diseases. (2006). Chronic hepatitis C: current disease management. National Digestive Diseases Information Clearinghouse. Retrieved March 16, 2009, from
-
(2006)
Chronic hepatitis C: current disease management
-
-
-
48
-
-
6044253416
-
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
-
Ong, J. P., & Younossi, Z. M. (2004). Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia. Cleveland Clinic Journal of Medicine, 71, S17-S21.
-
(2004)
Cleveland Clinic Journal of Medicine
, vol.71
-
-
Ong, J.P.1
Younossi, Z.M.2
-
49
-
-
37749051824
-
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders
-
Pearlman, B. L., Ehleben, C., & Saifee, S. (2007). Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology, 46, 1688-1694.
-
(2007)
Hepatology
, vol.46
, pp. 1688-1694
-
-
Pearlman, B.L.1
Ehleben, C.2
Saifee, S.3
-
50
-
-
0346157289
-
Viral hepatitis C
-
Poynard, T., Yuen, M.-F., Ratziu, V., & Lai, C. L. (2003). Viral hepatitis C. Lancet, 362, 2095-2100.
-
(2003)
Lancet
, vol.362
, pp. 2095-2100
-
-
Poynard, T.1
Yuen, M.-F.2
Ratziu, V.3
Lai, C.L.4
-
51
-
-
13844306621
-
Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction
-
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., ... Miller, A.H. (2005a). Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. Journal of Clinical Psychiatry, 66, 41-48.
-
(2005)
Journal of Clinical Psychiatry
, vol.66
, pp. 41-48
-
-
Raison, C.L.1
Borisov, A.S.2
Broadwell, S.D.3
Capuron, L.4
Woolwine, B.J.5
Jacobson, I.M.6
Miller, A.H.7
-
52
-
-
9944223329
-
Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C
-
Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., ... Miller, A.H. (2005b). Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C. Brain, Behavior, and Immunity, 19, 23-27.
-
(2005)
Brain, Behavior, and Immunity
, vol.19
, pp. 23-27
-
-
Raison, C.L.1
Broadwell, S.D.2
Borisov, A.S.3
Manatunga, A.K.4
Capuron, L.5
Woolwine, B.J.6
Miller, A.H.7
-
53
-
-
79960707083
-
-
Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day. Poster presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA.
-
Reau, N., Jensen, D., Hadziyannis, S., Messinger, D., & Fried, M. (2006). Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day. Poster presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA.
-
(2006)
-
-
Reau, N.1
Jensen, D.2
Hadziyannis, S.3
Messinger, D.4
Fried, M.5
-
54
-
-
33846246344
-
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
-
Reddy, K. R., Shiffman, M. L., Morgan, T. R., Zeuzem, S., Hadziyannis, S., Hamzeh, F. M., ... Fried, M. (2007). Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clinical Gastroenterology and Hepatology, 5, 124-129.
-
(2007)
Clinical Gastroenterology and Hepatology
, vol.5
, pp. 124-129
-
-
Reddy, K.R.1
Shiffman, M.L.2
Morgan, T.R.3
Zeuzem, S.4
Hadziyannis, S.5
Hamzeh, F.M.6
Fried, M.7
-
55
-
-
58349122475
-
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
-
Rodriguez-Torres, M., Jeffers, L. J., Sheikh, M. Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F. M., and Martin, P. (2009). Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. New England Journal of Medicine, 360, 257-267.
-
(2009)
New England Journal of Medicine
, vol.360
, pp. 257-267
-
-
Rodriguez-Torres, M.1
Jeffers, L.J.2
Sheikh, M.Y.3
Rossaro, L.4
Ankoma-Sey, V.5
Hamzeh, F.M.6
Martin, P.7
-
56
-
-
0037308288
-
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
-
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., ... Loeschke, K. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 37, 443-451.
-
(2003)
Hepatology
, vol.37
, pp. 443-451
-
-
Schaefer, M.1
Schmidt, F.2
Folwaczny, C.3
Lorenz, R.4
Martin, G.5
Schindlbeck, N.6
Loeschke, K.7
-
58
-
-
77952244103
-
-
Schering Corporation. Kenilworth, NJ: Schering Corporation.
-
Schering Corporation. (2009). PegIntron (peginterferon alfa-2b) injection. Kenilworth, NJ: Schering Corporation.
-
(2009)
PegIntron (peginterferon alfa-2b) injection
-
-
-
59
-
-
79960713753
-
-
Boceprevir (NS3 protease inhibitor) combination therapy in non responders: Phase II dose finding study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
-
Schiff, E., Poordad, F., Jacobson, I., Flamm, S., Bacon, B., Lawitz, E., ... Albrecht, J.K. (2008). Boceprevir (NS3 protease inhibitor) combination therapy in non responders: Phase II dose finding study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
-
(2008)
-
-
Schiff, E.1
Poordad, F.2
Jacobson, I.3
Flamm, S.4
Bacon, B.5
Lawitz, E.6
Albrecht, J.K.7
-
60
-
-
34447318385
-
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
-
Shiffman, M. L., Suter, F., Bacon, B. R., Nelson, D., Harley, H., Sola, R., et al. (2007). Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 357, 124-134.
-
(2007)
New England Journal of Medicine
, vol.357
, pp. 124-134
-
-
Shiffman, M.L.1
Suter, F.2
Bacon, B.R.3
Nelson, D.4
Harley, H.5
Sola, R.6
-
61
-
-
33745713376
-
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
-
Silva, M., Poo, J., Wagner, F., Jackson, M., Cutler, D., Grace, M., ... Laughlin, M. (2006). A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology, 45, 204-213.
-
(2006)
Journal of Hepatology
, vol.45
, pp. 204-213
-
-
Silva, M.1
Poo, J.2
Wagner, F.3
Jackson, M.4
Cutler, D.5
Grace, M.6
Laughlin, M.7
-
62
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147-1171.
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
63
-
-
3343012408
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
-
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., ... Dieterich, D.T. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351, 438-450.
-
(2004)
New England Journal of Medicine
, vol.351
, pp. 438-450
-
-
Torriani, F.J.1
Rodriguez-Torres, M.2
Rockstroh, J.K.3
Lissen, E.4
Gonzalez-Garcia, J.5
Lazzarin, A.6
Dieterich, D.T.7
-
64
-
-
23244457832
-
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
-
von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T., ... Zeuzem, S. (2005). Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129, 522-527.
-
(2005)
Gastroenterology
, vol.129
, pp. 522-527
-
-
von Wagner, M.1
Huber, M.2
Berg, T.3
Hinrichsen, H.4
Rasenack, J.5
Heintges, T.6
Zeuzem, S.7
-
65
-
-
0033799722
-
Estimating future hepatitis C morbidity, mortality, and costs in the United States
-
Wong, J. B., McQuillan, G. M., McHutchison, J. G., & Poynard, T. (2000). Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health, 90, 1562-1569.
-
(2000)
American Journal of Public Health
, vol.90
, pp. 1562-1569
-
-
Wong, J.B.1
McQuillan, G.M.2
McHutchison, J.G.3
Poynard, T.4
-
66
-
-
41549162418
-
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment
-
Younossi, Z. M., Nader, F. H., Bai, C., Sjogren, R., Ong, J. P., Collantes, R., ... Fang, Y. (2008). A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. Journal of Viral Hepatitis, 15, 370-378.
-
(2008)
Journal of Viral Hepatitis
, vol.15
, pp. 370-378
-
-
Younossi, Z.M.1
Nader, F.H.2
Bai, C.3
Sjogren, R.4
Ong, J.P.5
Collantes, R.6
Fang, Y.7
-
67
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., ... Albrecht, J.K. (2006). Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 44, 97-103.
-
(2006)
Journal of Hepatology
, vol.44
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
Sperl, J.4
Horsmans, Y.5
Cianciara, J.6
Albrecht, J.K.7
-
68
-
-
3042679031
-
Dynamics of hepatitis C virus infection
-
Zeuzem, S., & Herrmann, E. (2002). Dynamics of hepatitis C virus infection. Annals of Hepatology, 1, 56-63.
-
(2002)
Annals of Hepatology
, vol.1
, pp. 56-63
-
-
Zeuzem, S.1
Herrmann, E.2
|